Direct incorporation of the NKT-cell activator α-galactosylceramide into a recombinant Listeria monocytogenes improves breast cancer vaccine efficacy

British Journal of Cancer

Volumn 111, Issue 10, 2014, Pages 1945-1954

  Singh, M ^a   Quispe Tintaya, W ^a   Chandra, D ^a   Jahangir, A ^a   Venkataswamy, M M ^a,c   Ng, T W ^a   Sharma Kharkwal, S ^a   Carreno L J ^a,b   Porcelli, S A ^a   Gravekamp, C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CHILE   (Chile)

^c NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

a galactosylceramide; breast cancer; Listeria monocytogenes; metastases; NKT cells

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ANTIMETASTATIC AGENT; CANCER VACCINE; GAMMA INTERFERON; INTERLEUKIN 4; TUMOR ANTIGEN; ALPHA-GALACTOSYLCERAMIDE; GALACTOSYLCERAMIDE; MAGEB1 PROTEIN, MOUSE; MESSENGER RNA; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BREAST METASTASIS; CANCER IMMUNIZATION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; LISTERIA MONOCYTOGENES; LIVER NECROSIS; LIVER TOXICITY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SHORT TERM SURVIVAL; SPLEEN; T LYMPHOCYTE ACTIVATION; TUMOR VOLUME; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL ADHESION; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; GENETIC RECOMBINATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; METASTASIS; NATURAL KILLER CELL; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR CELL CULTURE; VACCINATION; WESTERN BLOTTING;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; BLOTTING, WESTERN; CANCER VACCINES; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; GALACTOSYLCERAMIDES; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LISTERIA MONOCYTOGENES; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINATION, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; VACCINATION;

EID: 84922479807     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.486     Document Type: Article

References (33)

1. Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52(6): 1399-1405
2. Behar SM, Porcelli SA (2007) CD1-restricted T cells in host defense to infectious diseases. Curr Top Microbiol Immunol 314: 215-250
3. Bendelac A, Savage PB, Teyton L (2007) The biology of NKT cells. Annu Rev Immunol 25: 297-336
4. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB (2003) Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 4(12): 1230-1237
5. Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, van't Veer L, Viale G, Krop I, Winer E (2012) 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 21(3): 242-252
6. Castro F, Leal B, Denny A, Bahar R, Lampkin S, Reddick R, Lu S, Gravekamp C (2009) Vaccination with Mage-b DNA induces CD8 T-cell responses at young but not old age in mice with metastatic breast cancer. Br J Cancer 101(8): 1329-1337
7. Chambers RS, Johnston SA (2003) High-level generation of polyclonal antibodies by genetic immunization. Nat Biotechnol 21(9): 1088-1092
8. Chandra D, Jahangir A, Quispe-Tintaya W, Einstein MH, Gravekamp C (2013) Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes-based immunotherapy against metastatic breast cancer in young and old mice. Br J Cancer 108(11): 2281-2290
9. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58(1): 49-59
10. Gajewski TF, Meng Y, Harlin H (2006) Immune suppression in the tumor microenvironment. J Immunother 29(3): 233-240
11. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22
12. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y (2001) Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 167(11): 6471-6479
13. Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, Schmidt R, Harris AL, Old L, Cerundolo V (2003) NKT cells enhance CD4' and CD8' T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 171(10): 5140-5147
14. Kim SH, Castro F, Gonzalez D, Maciag PC, Paterson Y, Gravekamp C (2008) Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases. Br J Cancer 99(5): 741-749
15. Kim SH, Castro F, Paterson Y, Gravekamp C (2009) High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res 69(14): 5860-5866
16. Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dreno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont AM, Marchand M (2005) Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 117(4): 596-604
17. Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Håkansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T, Stoter G (2003) Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 39(1): 70-77
18. Metelitsa LS (2011) Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin Immunol 140(2): 119-129
19. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA (2002) A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8(12): 1369-1375
20. North RJ, Conlan JW (1998) Immunity to Listeria monocytogenes. Chem Immunol 70: 1-20
21. Paterson Y, Maciag PC (2005) Listeria-based vaccines for cancer treatment. Curr Opin Mol Ther 7(5): 454-460
22. Quispe-Tintaya W, Chandra D, Jahangir A, Harris M, Casadevall A, Dadachova E, Gravekamp C (2013) Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer. Proc Natl Acad Sci USA 110(21): 8668-8673
23. Schneiders FL, Scheper RJ, Von Blomberg BM, Woltman AM, Janssen HL, van den Eertwegh AJ, Verheul HM, De Gruijl TD, van der Vliet HJ (2011) Clinical experience with alpha-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin Immunol 140(2): 130-141
24. Shortman K, Heath WR (2010) The CD8' dendritic cell subset. Immunol Rev 234(1): 18-31
25. Singh R, Dominiecki ME, Jaffee EM, Paterson Y (2005) Fusion to listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J Immunol 175(6): 3663-3673
26. Soudja SM, Ruiz AL, Marie JC, Lauvau G (2012) Inflammatory monocytes activate memory CD8(') T and innate NK lymphocytes independent of cognate antigen during microbial pathogen invasion. Immunity 37(3): 549-562
27. Sypniewska RK, Hoflack L, Tarango M, Gauntt S, Leal BZ, Reddick RL, Gravekamp C (2005) Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy. Breast Cancer Res Treat 91(1): 19-28
28. Venkataswamy MM, Baena A, Goldberg MF, Bricard G, Im JS, Chan J, Reddington F, Besra GS, Jacobs Jr WR, Porcelli SA (2009) Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin. J Immunol 183(3): 1644-1656
29. Vremec D, O'Keeffe M, Hochrein H, Fuchsberger M, Caminschi I, Lahoud M, Shortman K (2007) Production of interferons by dendritic cells, plasmacytoid cells, natural killer cells, and interferon-producing killer dendritic cells. Blood 109(3): 1165-1173
30. Wilson MT, Johansson C, Olivares-Villagomez D, Singh AK, Stanic AK, Wang CR, Joyce S, Wick MJ, Van Kaer L (2003) The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA 100(19): 10913-10918
31. Yamasaki K, Horiguchi S, Kurosaki M, Kunii N, Nagato K, Hanaoka H, Shimizu N, Ueno N, Yamamoto S, Taniguchi M, Motohashi S, Nakayama T, Okamoto Y (2011) Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin Immunol 138(3): 255-265
32. Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD (2012) The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 36(3): 237-248
33. Yu KO, Im JS, Molano A, Dutronc Y, Illarionov PA, Forestier C, Fujiwara N, Arias I, Miyake S, Yamamura T, Chang YT, Besra GS, Porcelli SA (2005) Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci USA 102(9): 3383-3388